StockMarketWire.com - An evaluation of ANGLE's Parsortix system by the University Medical Centre Hamburg-Eppendorf (UKE) has been published in the International Journal of Cancer.

The paper is entitled "A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells" 1. The UKE cancer research centre is a world-leading authority on the emerging field of liquid biopsy and, in 2015 alone, published 17 scientific papers in high ranking journals on different aspects of the application of liquid biopsy in cancer care. UKE's evaluation demonstrated significant advantages of the Parsortix system in harvesting circulating tumour cells (CTCs) compared to antibody-based and filtration CTC enrichment systems.

The publication determined that the Parsortix system enables the harvesting of CTCs at a high purity and provides viable tumour cells that are easily accessible and ready for a broad range of molecular and functional analyses.

99 per cent of the harvested CTCs from both spiked and patient samples were viable after processing and still functional for downstream molecular analysis as demonstrated by mRNA characterisation and array based comparative genomic hybridisation.




At 2:50pm: [LON:AGL] Angle PLC share price was +0.25p at 68.5p



Story provided by StockMarketWire.com